Fungi

A single patient, forty-five days post-transplant. The disagreement isn’t about whether the drug is right for the disease — it’s about whether his own metabolism has already made the standard dose meaningless.

A single patient, fourteen months into therapy that had been working. The disagreement is whether a worsening cavity means the organism outran the drug, or the drug never reached it in the first place.

A single patient, cleared systemically and about to step down early. The disagreement is whether an eye exam most cases never need has just changed what “controlled” actually means.

A single patient, already known to carry the outbreak organism before she got sick. The disagreement is whether the unit’s own recent numbers or her own three-week-old culture is the better guide, with no time to wait for both.

A single patient, eight months into an otherwise uneventful transplant course. The disagreement is whether a duration built for a different population fits a burden this high, or whether the kidney underneath it can’t afford to find out.

A single patient, in diabetic ketoacidosis with a fungal infection that won’t wait for her glucose to normalize. The disagreement is how many hours of correction is enough before the clock on the infection outruns the clock on the anesthesia.

A single patient, nine weeks pregnant with disease mild enough that most patients wouldn’t be treated at all. The disagreement is whether pregnancy alone should change that answer, and whether the standard drug is even a safe way to find out.

A single patient, on a biologic that predisposed him to this exact infection. The disagreement was never really about the antifungal choice — it was about correcting the wrong reason everyone assumed for it.

A single patient, whose new headache arrived before any test could confirm what it might mean. The disagreement is whether to treat the exam finding now or wait for imaging that won’t change the induction regimen either way.

A single patient, whose two standard fallback regimens both failed for reasons that turned out to share the same underlying mechanism. The disagreement is which of the two options left standing is actually the safer bet.

A single patient, eight days into the exact clinical picture empiric antifungal therapy was built to cover — except his own tests keep coming back clean. The disagreement is whether a real negative result should count for as much as a start date on a calendar.

A single patient, whose infected catheter is also her only way to survive the week. The disagreement is whether guideline-recommended removal still applies when the alternative isn’t actually available yet.

A single patient, on his third recurrence, this time genuinely resistant rather than simply recurring. The disagreement is less about which drug to use than about correcting an assumption before it becomes the next mistake.

A single patient, whose regimen finally worked not because the drug changed, but because someone checked his actual week before choosing it.